⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
AARD News
Aardvark Therapeutics, Inc. Common Stock
Aardvark Therapeutics Announces Establishment of New U.S. Subsidiary to Support Development of Its Dermatology Pipeline; Bryan Jones Named Chief Executive Officer
globenewswire.com
AARD
Aardvark Therapeutics Announces FDA Submission and IRB Approval of Amended Trial Protocol for Lead Candidate ARD-101, Expanding Eligibility in Phase 3 Study of Prader-Willi Syndrome
globenewswire.com
AARD
Aardvark Therapeutics Announces First Patient Dosed in Australia in HERO Phase 3 Trial for Prader-Willi Syndrome
globenewswire.com
AARD
Aardvark Therapeutics to Present at Upcoming Investor Conferences in December
globenewswire.com
AARD
Aardvark Therapeutics Reports Third Quarter 2025 Financial Results and Provides Pipeline and Business Updates
globenewswire.com
AARD
Aardvark Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
globenewswire.com
AARD
Aardvark Therapeutics Presents Data Supporting its Metabolic Obesity Pipeline Programs at ObesityWeek 2025
globenewswire.com
AARD
Aardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
globenewswire.com
AARD
Aardvark Therapeutics to Present at Upcoming Investor Conferences in November
globenewswire.com
AARD
Aardvark Therapeutics Announces FDA Alignment on Protocol Amendment Expanding Phase 3 HERO Trial Population for Prader-Willi Syndrome
globenewswire.com
AARD